Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunosuppressive effects of statins.

François Mach1

  • 1Medicine Department, Cardiology Division, Foundation for Medical Research, Geneva Medical School, University Hospital, 64 Avenue Roseraie, 1211 Geneva, Switzerland.

Atherosclerosis. Supplements
|June 5, 2002
PubMed
Summary

Statins, commonly used for lowering lipids, surprisingly inhibit the induction of Major Histocompatibility Complex class II (MHC class II) molecules. This action positions statins as novel immunomodulators with potential immunosuppressive applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Weight change and long-term cardiovascular outcomes in overweight and obese patients after acute coronary syndromes.

European heart journal open·2026
Same author

Safety of low lipoprotein(a) levels: the FOURIER trial.

European heart journal·2026
Same author

Revue medicale suisse·2026
Same author

[Chronic coronary syndrome : advanced cardiac imaging].

Revue medicale suisse·2026
Same author

[Chagas cardiomyopathy].

Revue medicale suisse·2026
Same author

Erratum to "2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias" [Atherosclerosis, 409, (October 2025), 120479].

Atherosclerosis·2026

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Statins (HMG-CoA reductase inhibitors) are established lipid-lowering drugs.
  • Previous research hinted at improved outcomes in organ transplantation with statin use, but their immunomodulatory role was unclear.
  • Major histocompatibility complex class II (MHC class II) molecules are crucial for T lymphocyte activation and immune response regulation.

Purpose of the Study:

  • To investigate the potential immunomodulatory effects of statins.
  • To determine if statins influence the expression of MHC class II molecules.
  • To elucidate the mechanism by which statins might affect immune responses.

Main Methods:

  • The study focused on the induction of MHC class II expression by interferon-gamma (IFN-gamma).

Related Experiment Videos

  • Investigated the role of the transactivator CIITA in MHC class II regulation.
  • Examined the effect of statins on the inducible promoter IV of CIITA.

    • Main Results:

    • Statins were found to directly inhibit the IFN-gamma-induced expression of MHC class II molecules.
    • This inhibition is specific to inducible MHC class II expression, not affecting constitutive expression.
    • Statins act by inhibiting the inducible promoter IV of the transactivator CIITA.

    Conclusions:

    • Statins function as novel immunomodulators by repressing inducible MHC class II expression.
    • This mechanism provides a scientific basis for using statins as immunosuppressors.
    • Potential applications include organ transplantation and other immune-related pathologies.